| Year |
Citation |
Score |
| 2024 |
Loria M, Gilbert D, Tabernacki T, Maravillas MA, McNamara M, Gupta S, Mishra K. Incidence of prostate cancer in transgender women in the US: a large database analysis. Prostate Cancer and Prostatic Diseases. PMID 38326392 DOI: 10.1038/s41391-024-00804-4 |
0.438 |
|
| 2022 |
Harrison MR, Davis PG, Khouri MG, Bartlett DB, Gupta RT, Armstrong AJ, McNamara MA, Zhang T, Anand M, Onyenwoke K, Edwardson S, Craig D, Michalski M, Wu Y, Oyekunle T, et al. A randomized controlled trial comparing changes in fitness with or without supervised exercise in patients initiated on enzalutamide and androgen deprivation therapy for non-metastatic castration-sensitive prostate cancer (EXTEND). Prostate Cancer and Prostatic Diseases. PMID 35273377 DOI: 10.1038/s41391-022-00519-4 |
0.512 |
|
| 2021 |
George DJ, Halabi S, Heath EI, Sartor AO, Sonpavde GP, Das D, Bitting RL, Berry W, Healy P, Anand M, Winters C, Riggan C, Kephart J, Wilder R, Shobe K, ... ... McNamara M, et al. A prospective trial of abiraterone acetate plus prednisone in Black and White men with metastatic castrate-resistant prostate cancer. Cancer. PMID 33951180 DOI: 10.1002/cncr.33589 |
0.595 |
|
| 2021 |
Zhang T, Agarwal A, Almquist RG, Runyambo D, Park S, Bronson E, Boominathan R, Rao C, Anand M, Oyekunle T, Healy P, McNamara MA, Ware K, Somarelli JA, George DJ, et al. Expression of immune checkpoints on circulating tumor cells in men with metastatic prostate cancer. Biomarker Research. 9: 14. PMID 33602330 DOI: 10.1186/s40364-021-00267-y |
0.399 |
|
| 2021 |
Zhang T, Koontz BF, Tagawa ST, Nagar H, Bitting RL, Frizzell B, Nordquist LT, Rasmussen J, Wilder R, Anand M, Winters C, Riggan C, Fernandez E, Healy P, Oyekunle T, ... ... McNamara MA, et al. Interim analysis of STARTAR: A phase II salvage trial of androgen receptor (AR) inhibition with androgen deprivation therapy (ADT) and apalutamide with radiation therapy (RT) followed by docetaxel in men with PSA recurrent prostate cancer (PC) after radical prostatectomy (RP). Journal of Clinical Oncology. 39: 90-90. DOI: 10.1200/JCO.2021.39.6_SUPPL.90 |
0.604 |
|
| 2019 |
Zhu J, Tucker M, Marin D, Gupta RT, Healy P, Humeniuk M, Jarvis C, Zhang T, McNamara M, George DJ, Wu Y, Lisi S, Armstrong AJ. Clinical utility of FoundationOne tissue molecular profiling in men with metastatic prostate cancer. Urologic Oncology. PMID 31327751 DOI: 10.1016/j.urolonc.2019.06.015 |
0.508 |
|
| 2019 |
McNamara MA, Oyekunle T, Chin BB, Oldan J, Anand A, Ritz M, Shantzer L, Anand M, Armstrong AJ, George DJ. Patterns of response and progression in bone and soft tissue during and after treatment with radium-223 for metastatic castrate-resistant prostate cancer. The Prostate. PMID 31045266 DOI: 10.1002/pros.23822 |
0.422 |
|
| 2019 |
Holl EK, McNamara MA, Healy P, Anand M, Concepcion RS, Breland CD, Dumbudze I, Tutrone R, Shore N, Armstrong AJ, Harrison M, Wallace JA, Wu Y, George DJ. Prolonged PSA stabilization and overall survival following sipuleucel-T monotherapy in metastatic castration-resistant prostate cancer patients. Prostate Cancer and Prostatic Diseases. PMID 30980027 DOI: 10.1038/S41391-019-0144-3 |
0.575 |
|
| 2019 |
Labriola MK, Batich KA, Zhu J, McNamara MA, Harrison MR, Armstrong AJ, George DJ, Zhang T. Immunotherapy Is Changing First-Line Treatment of Metastatic Renal-Cell Carcinoma. Clinical Genitourinary Cancer. PMID 30858035 DOI: 10.1016/J.Clgc.2019.01.017 |
0.383 |
|
| 2019 |
Harrison MR, Khouri M, Armstrong AJ, Zhang T, McNamara MA, Anand M, Bratt E, Hood H, Coyne B, Wu Y, Healy P, George DJ. PEAX: Men with metastatic castrate-resistant prostate cancer (mCRPC) treated with either sipuleucel-T (SIP-T), enzalutamide (ENZA) or abiraterone acetate (ABI) undergoing cardiopulmonary exercise testing (CPET). Journal of Clinical Oncology. 37: 281-281. DOI: 10.1200/Jco.2019.37.7_Suppl.281 |
0.536 |
|
| 2019 |
McNamara MA, George DJ, Ramaswamy K, Lechpammer S, Mardekian J, Schultz NM, Wang L, Baser O, Huang A, Freedland SJ. Overall survival by race in chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate or enzalutamide. Journal of Clinical Oncology. 37: 212-212. DOI: 10.1200/JCO.2019.37.7_SUPPL.212 |
0.418 |
|
| 2019 |
Zhang T, Koontz BF, Tagawa ST, Nagar H, Bitting RL, Frizzell B, Rasmussen J, Wilder R, Anand M, Winters C, Riggan C, Lee A, Healy P, Wu Y, McNamara MA, et al. A phase II Salvage Trial of AR Inhibition with ADT and Apalutamide with Radiation therapy followed by docetaxel in men with PSA recurrent prostate cancer (PC) after radical prostatectomy (STARTAR). Journal of Clinical Oncology. 37. DOI: 10.1200/Jco.2019.37.15_Suppl.Tps5097 |
0.581 |
|
| 2019 |
Zhu J, Tucker MD, Kao C, Labriola M, Cheris S, Datto MB, Wu Y, Healy P, Gupta S, Kirtane K, Gupta RT, Marin D, Zhang T, McNamara MA, Harrison MR, et al. Immune checkpoint inhibitor response in tumors with LRP1B variants. Journal of Clinical Oncology. 37: e14291-e14291. DOI: 10.1200/Jco.2019.37.15_Suppl.E14291 |
0.519 |
|
| 2019 |
Mara A, Zhu J, Wu Y, Callis T, Yang S, Esplin ED, Nussbaum RL, Zhang T, McNamara MA, Harrison MR, George DJ, Cooney KA, Armstrong AJ. Prevalence of pathogenic germline variants in DNA repair by race, age, and ethnicity in men with prostate cancer. Journal of Clinical Oncology. 37: 5062-5062. DOI: 10.1200/Jco.2019.37.15_Suppl.5062 |
0.543 |
|
| 2018 |
Harrison MR, Davis PG, Khouri MG, Gupta RT, Armstrong AJ, McNamara MA, Zhang T, Anand M, Onyenwoke K, Hood H, Edwardson S, Craig D, Wu Y, Healy P, Coyne B, et al. EXTEND: Safety and efficacy of exercise training in men receiving enzalutamide (ENZ) in combination with conventional androgen deprivation therapy (ADT) for hormone naïve prostate cancer (HSPC). Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: viii623-viii624. PMID 32137677 DOI: 10.1093/annonc/mdy300.064 |
0.57 |
|
| 2018 |
McNamara M, Sweeney C, Antonarakis ES, Armstrong AJ. The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation. Prostate Cancer and Prostatic Diseases. 21: 306-318. PMID 29263421 DOI: 10.1038/s41391-017-0014-9 |
0.487 |
|
| 2018 |
George DJ, Heath EI, Sartor AO, Sonpavde G, Berry WR, Healy P, Winters C, Riggan C, Anand M, Kephart J, Milowsky MI, Fleming MT, Balaji KC, Zhang T, Bitting RL, ... ... McNamara MA, et al. Abi Race: A prospective, multicenter study of black (B) and white (W) patients (pts) with metastatic castrate resistant prostate cancer (mCRPC) treated with abiraterone acetate and prednisone (AAP). Journal of Clinical Oncology. 36: LBA5009-LBA5009. DOI: 10.1200/Jco.2018.36.18_Suppl.Lba5009 |
0.507 |
|
| 2018 |
Shantzer L, Ritz M, Chin BB, Oldan J, Anand A, Oyekunle T, Anand M, Armstrong AJ, George DJ, McNamara MA. Patterns of bone scan and pain response following treatment with Ra-223 in metastatic castrate resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 36: e17011-e17011. DOI: 10.1200/JCO.2018.36.15_SUPPL.E17011 |
0.331 |
|
| 2018 |
Zhang T, Austin RG, Park SE, Runyambo D, Boominathan R, Rao C, Bronson E, Anand M, Healy P, George DJ, McNamara MA, Armstrong AJ. Expression of immune checkpoints (ICs) on circulating tumor cells (CTCs) in men with metastatic prostate cancer (mPC). Journal of Clinical Oncology. 36: 5059-5059. DOI: 10.1200/JCO.2018.36.15_SUPPL.5059 |
0.395 |
|
| 2017 |
Humeniuk MS, Gupta RT, Healy P, McNamara M, Ramalingam S, Harrison M, George D, Zhang T, Wu Y, Armstrong AJ. Platinum sensitivity in metastatic prostate cancer: does histology matter? Prostate Cancer and Prostatic Diseases. PMID 29230006 DOI: 10.1038/S41391-017-0017-6 |
0.605 |
|
| 2017 |
Humeniuk MS, Gupta RT, McNamara MA, Ramalingam S, Harrison MR, George DJ, Wu Y, Healy P, Armstrong AJ. Association of neuroendocrine phenotype with platinum chemotherapy outcomes in men with metastatic prostate cancer. Journal of Clinical Oncology. 35: e16532-e16532. DOI: 10.1200/Jco.2017.35.15_Suppl.E16532 |
0.615 |
|
| 2015 |
McNamara MA, George DJ. Pain, PSA flare, and bone scan response in a patient with metastatic castration-resistant prostate cancer treated with radium-223, a case report. Bmc Cancer. 15: 371. PMID 25948240 DOI: 10.1186/s12885-015-1390-y |
0.385 |
|
| 2015 |
McNamara M, Berry W. Complete Biochemical Response (Prostate Specific Antigen) to Sipuleucel-T in Metastatic Castrate-Resistant Prostate Cancer: A Case Report with Docetaxel Chemotherapy Administered Just before Sipuleucel-T Clinical Genitourinary Cancer. 13: e361-e364. PMID 25735199 DOI: 10.1016/j.clgc.2015.02.004 |
0.463 |
|
| Show low-probability matches. |